Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Wenquing Yao Biography and Net Worth

EVP of Incyte

Dr. Wenqing Yao, Ph.D., is Executive Vice President, Head of Discovery Chemistry of Incyte Corporation. He has served as Executive Vice President, Head of Discovery Chemistry since October 2014. Dr. Yao joined Incyte as Director, Chemistry in February 2002 and held roles of increasing responsibility at Incyte. Prior to joining Incyte, Dr. Yao held scientific research positions with DuPont Pharmaceuticals and Bristol-Myers Squibb Company from 1996 to 2002. Dr. Yao received his B.S. in chemistry from Xuzhou Normal University, his M.S. in organic chemistry from NanKai University and his Ph.D. in organic/medicinal chemistry from the University of Pennsylvania.

What is Wenquing Yao's net worth?: The estimated net worth of Wenquing Yao is at least $7.41 million as of January 25th, 2021. Dr. Yao owns 145,343 shares of Incyte stock worth more than $7,412,493 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Yao may own. Learn More about Wenquing Yao's net worth.
How do I contact Wenquing Yao?: The corporate mailing address for Dr. Yao and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Wenquing Yao's contact information.
Has Wenquing Yao been buying or selling shares of Incyte?: Wenquing Yao has not been actively trading shares of Incyte in the last ninety days. Most recently, Yao Wenqing sold 27,194 shares of the business's stock in a transaction on Tuesday, June 29th. The shares were sold at an average price of $85.37, for a transaction totalling $2,321,551.78. Learn More on Wenquing Yao's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (President), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 867 shares worth more than $54,750.60. The most recent insider tranaction occured on January, 2nd when EVP Vijay K Iyengar sold 657 shares worth more than $42,705.00. Insiders at Incyte own 17.5% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 1/2/2024.

Wenquing Yao Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/29/2021	Sell	27,194	$85.37	$2,321,551.78
1/25/2021	Sell	21,545	$100.00	$2,154,500.00	145,343
7/6/2020	Sell	16,553	$107.32	$1,776,467.96	158,849
12/2/2019	Sell	16,835	$95.00	$1,599,325.00	98,473
11/29/2019	Sell	3,165	$95.00	$300,675.00	98,473
11/1/2019	Sell	7,960	$85.00	$676,600.00	103,268
10/29/2019	Sell	2,040	$85.00	$173,400.00	47,348
1/17/2019	Sell	15,354	$77.61	$1,191,623.94	49,763
1/7/2019	Sell	10,000	$75.00	$750,000.00	45,217
11/3/2015	Sell	5,786	$124.78	$721,977.08	21,371
4/17/2015	Sell	7,150	$102.04	$729,586.00
4/13/2015	Sell	23,000	$95.18	$2,189,140.00
4/7/2015	Sell	20,031	$90.13	$1,805,394.03

Wenquing Yao Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $50.94

$50.35

$51.85

50 Day Range

MA: $57.06

$51.65

$61.00

2 Week Range

Now: $50.94

$50.27

$75.74

Volume

1,361,792 shs

Average Volume

1,718,876 shs

Market Capitalization

$11.44 billion

P/E Ratio

19.22

Dividend Yield

N/A

Beta

0.65